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Bioavailability and Pharmacokinetics of Oral Meloxicam in Llamas
Abstract
South American camelids in the United States have rapidly developed into an important agricultural industry
in need of veterinary services. Pain management is challenging in camelids because there are no drugs
currently approved by the U.S. Food and Drug Administration for use in these species. Dosage regimens used
for many therapeutic drugs have been extrapolated from other ruminants; however, the pharmacokinetics, in
camelids, may differ from those of other species. Studies investigating the pharmacokinetics of
cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drugs in camelids are deficient in the
published literature. Six adult llamas (121- 168 kg) were administered either a 1 mg/kg dose of oral or a 0.5
mg/kg dose of IV meloxicam in a randomized cross-over design with an 11 day washout period between
treatments. Plasma samples collected up to 96 hours post-administration were analyzed by high pressure
liquid chromatography and mass spectrometry detection (HPLC-MS) followed by non-compartmental
pharmacokinetic analysis. A mean peak plasma concentration (CMAX) of 1.314 μg/mL (Range: 0.826 –
1.776 μg/mL) was recorded at 21.4 hours (Range: 12.0 – 24.0 hours) with a half-life (T ½ λz) of 22.7 hours
(Range: 18.0 – 30.8 hours) after oral meloxicam administration. In comparison, a half-life (T ½ λz) of 17.4
hours (Range: 16.2 – 20.7 hours) was demonstrated with IV meloxicam administration. The oral
bioavailability (F) of meloxicam (dose normalized) was 76% (Range: 48 – 92%). No adverse effects
associated with either treatment modality were observed in the llamas. The mean bioavailability (F) of oral
meloxicam was 76% indicating a high degree of gastrointestinal absorption. Plasma meloxicam concentrations
>0.2 μg/mL were maintained for up to 72 h after oral administration; >0.2 μg/mL is considered to be the
concentration of meloxicam required for analgesic effects in other species such as the horse. These data
suggest that a single dosage of oral meloxicam at 1 mg/kg could potentially maintain therapeutic
concentrations in plasma for up to 3 days in adult llamas.
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Bioavailability and pharmacokinetics of oral
meloxicam in llamas
Amanda J Kreuder1, Johann F Coetzee1,3*, Larry W Wulf3, Jennifer A Schleining1,4, Butch KuKanich5,
Lori L Layman1 and Paul J Plummer1,2
Abstract
Background: South American camelids in the United States have rapidly developed into an important agricultural
industry in need of veterinary services. Pain management is challenging in camelids because there are no drugs
currently approved by the U.S. Food and Drug Administration for use in these species. Dosage regimens used for
many therapeutic drugs have been extrapolated from other ruminants; however, the pharmacokinetics, in camelids,
may differ from those of other species. Studies investigating the pharmacokinetics of cyclooxygenase-2 (COX-2)
selective non-steroidal anti-inflammatory drugs in camelids are deficient in the published literature. Six adult
llamas (121- 168 kg) were administered either a 1 mg/kg dose of oral or a 0.5 mg/kg dose of IV meloxicam in a
randomized cross-over design with an 11 day washout period between treatments. Plasma samples collected up to
96 hours post-administration were analyzed by high pressure liquid chromatography and mass spectrometry
detection (HPLC-MS) followed by non-compartmental pharmacokinetic analysis.
Results: A mean peak plasma concentration (CMAX) of 1.314 μg/mL (Range: 0.826 – 1.776 μg/mL) was recorded at
21.4 hours (Range: 12.0 – 24.0 hours) with a half-life (T ½ λz) of 22.7 hours (Range: 18.0 – 30.8 hours) after oral
meloxicam administration. In comparison, a half-life (T ½ λz) of 17.4 hours (Range: 16.2 – 20.7 hours) was
demonstrated with IV meloxicam administration. The oral bioavailability (F) of meloxicam (dose normalized) was
76% (Range: 48 – 92%). No adverse effects associated with either treatment modality were observed in the llamas.
Conclusions: The mean bioavailability (F) of oral meloxicam was 76% indicating a high degree of gastrointestinal
absorption. Plasma meloxicam concentrations >0.2 μg/mL were maintained for up to 72 h after oral administration;
>0.2 μg/mL is considered to be the concentration of meloxicam required for analgesic effects in other species such
as the horse. These data suggest that a single dosage of oral meloxicam at 1 mg/kg could potentially maintain
therapeutic concentrations in plasma for up to 3 days in adult llamas.
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Background
Over the past few decades, North America has seen a
rapid increase in the number of South American came-
lids raised for fiber, show and companionship. Along
with the increase in animal numbers has come an
increase in interest for veterinary care and appropriate
drug therapies for these animals. To date, however, there
are no drugs currently approved by the Food and Drug
Administration for use in camelids in the United States.
Thus, extra-label use of common veterinary therapeutic
drugs in camelids is routine in practice, yet there gener-
ally remains a lack of pharmacokinetic (PK) data in
camelids. Dosages used have been extrapolated from
other large animal species, including cattle, horses, and
other small ruminant species. Particularly in regards to
oral administration and bioavailability of medications,
this practice has proven to be inadequate in some of the
camelid pharmacokinetic studies published to date [1-5].
In addition, although not common practice in the United
States, llama meat is available for purchase through vari-
ous outlets. If this market were to expand, scientific data
* Correspondence: hcoetzee@iastate.edu
1Department of Veterinary Diagnostic and Production Animal Medicine
(VDPAM), College of Veterinary Medicine, Iowa State University, Ames, IA
50011, USA
3Cyclone Custom Analyte Detection Service (CYCADS), College of Veterinary
Medicine, Iowa State University, Ames, IA 50011, USA
Full list of author information is available at the end of the article
© 2012 Kreuder et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Kreuder et al. BMC Veterinary Research 2012, 8:85
http://www.biomedcentral.com/1746-6148/8/85
on drug withdrawal time in llamas are currently lacking
to ensure the safety of this non-traditional food supply.
Non-steroidal anti-inflammatory drugs (NSAIDS) are
commonly utilized in large animal veterinary practice for
relief of pain, fever, and inflammation. Increasing public
awareness of animal welfare will likely continue to make
proper use of NSAIDS a priority in the treatment of all
domestic animals for painful inflammatory conditions.
Therefore, knowledge of the pharmacokinetics of NSAIDS
in the specific species of interest will be required to pro-
vide for safe and efficacious use. Previous studies have
been completed evaluating the pharmacokinetics of the
NSAIDS flunixin meglumine [6], ketoprofen [7], and
phenylbutazone [8] in llamas, however, studies investi-
gating the pharmacokinetics, in camelids, of non-
steroidal anti-inflammatory drugs considered to be
cyclooxygenase-2 (COX-2) selective are deficient in the
published literature. In general, the beneficial thera-
peutic actions of NSAIDS are thought to be related to
inhibition of COX-2, and the undesirable side effects
such as gastrointestinal ulceration due to non-selective
inhibition of both COX isoforms[9]. Thus, the ability to
utilize a COX-2 selective NSAID in a field setting for
management of pain and inflammation may be desirable.
Meloxicam is an NSAID of the oxicam class which
exerts its effect via selective inhibition of the COX-2 en-
zyme, thereby preventing prostaglandin synthesis which
can lead to pain, fever and inflammation. Meloxicam is
approved for use in cattle in the European Union (EU) as
adjunctive therapy for acute respiratory disease, diarrhea
and acute mastitis [10], and in Canada for alleviation of
pain at debudding and improved performance in calves
with diarrhea[11]. In companion animals meloxicam is
approved in the EU, United States, and Canada for use
in dogs for treatment of pain associated with osteoarth-
ritis and cats for control of perioperative pain [12]. In
addition, meloxicam has been shown in cattle to effect-
ively suppress the inflammatory response to experimental
endotoxin administration [13]. The availability of an oral
formulation of meloxicam makes it particularly attractive
for field use in treatment of inflammatory conditions.
As the pharmacokinetics of meloxicam in llamas have
not been reported to date in the published literature, the
objective of this study was to evaluate the pharmacokin-
etics of IV and oral meloxicam administration, and from
this data determine the oral bioavailability in llamas. If
oral meloxicam results in plasma concentrations com-
parable to that of parenteral administration, it may pro-
vide a practical and cost-effective method for relief of
pain and inflammation in llamas.
Results
No adverse effects were noted after IV or oral meloxi-
cam administration. The pharmacokinetic parameters of
meloxicam in llamas following IV administration of
0.5 mg/kg and oral administration at 1 mg/kg are shown
in Table 1 and Figure 1. Following IV administration,
meloxicam demonstrated a moderately small mean vol-
ume of distribution (Vss) of 0.235 L/kg (Range: 0.206 –
0.237 L/kg) and a relatively slow mean clearance (Cl)
from the central compartment of 0.19 ml/min/kg
(Range: 0.151 – 0.192 mL/kg/min). This was associated
with a long mean plasma half-life (T ½ λz) of 17.4 hours
(Range: 16.2 – 20.7 hours).
A mean peak plasma meloxicam concentration (CMAX)
of 1.314 μg/mL (range 0.826 – 1.776 μg/mL) was
recorded at approximately 21.4 hours (range 12.0 –
24.0 hours) following oral administration. This was asso-
ciated with a mean plasma half-life (T ½ λz) of 22.7 hours
(Range: 18 – 30.8 hours) which is extended when
compared to the T ½ λz observed with IV administra-
tion. The area under the curve extrapolated to infinity
(AUCINF) following oral administration relative to IV
administration resulted in a dose normalized calculated
fraction of the drug absorbed (F) being 0.76 (range
0.48 – 0.92).
Table 2 provides a summary of the hematological para-
meters measured prior to and after the second phase of
treatment with meloxicam (n = 3 for both oral and IV
treatments). A reference range has not been established
for this species at this lab; therefore standard reference
ranges from Oregon State University Diagnostic Lab
[14] were utilized by our laboratory to evaluate results.
Some minor abnormalities in measured blood para-
meters were noted, however, all were considered to be of
minimal clinical significance.
Discussion
An ideal anti-inflammatory drug for use in field settings
requires the ability for oral administration, does not
require multiple doses per day, minimizes the number of
administration periods necessary to achieve adequate
drug concentrations, and is cost-effective. The purpose
of this study was to investigate the pharmacokinetics
and oral bioavailability of meloxicam in llamas. The
results of this study indicate that a mean CMAX of
1.314 μg/mL occurred approximately 21.4 hours after
oral administration. A relatively slow clearance resulted
in a T ½ λz of 22.7 hours. Oral meloxicam demonstrated
a high degree of gastrointestinal absorption and oral bio-
availability when dose normalized in comparison to IV
administration. These findings suggest that oral meloxi-
cam may provide an effective means of providing long-
lasting analgesic and anti-inflammatory effects to llamas
in a field setting once efficacy has been demonstrated.
During the study, one of the llamas exhibited a large
increase in weight (from 142.7 kg to 164.1 kg) between
the first treatment (IV) and the second treatment (oral).
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This increase is considered to be too large for normal
weight gain over an 11 day period (approximately 2 kg/day),
thus error in weighing the animal was likely the source
of variation. Previous hospital records of this animal
indicate a weight of 172.7 kg approximately one month
prior to initiation of the trial. Therefore, it is highly likely
that the weight for the first treatment was recorded as
falsely low at 142.7 kg and that the weight for the second
treatment at 164.1 kg (which was verified with a second
weighing at the time of the discovery of the discrepancy)
Figure 1 Plasma meloxicam concentrations in llamas after intravenous (IV) administration at 0.5 mg/kg and oral (PO) administration
at 1 mg/kg.
Table 1 Meloxicam pharmacokinetic parameters following a single IV (0.5 mg/kg) or PO (1.0 mg/kg) administration
IV PO
Parameter (Units) Geometric Mean Min Median Max Geometric Mean Min Median Max
AUC extrapolated (%) 1.9 1.4 1.7 3.5 6.6 3.6 6.3 13.1
AUCINF (hr*μg/mL) 43.96 31.44 43.45 55.60 68.35 52.37 74.98 79.24
Cl (mL/min/kg) 0.190 0.151 0.192 0.260 N/A N/A N/A N/A
Cl/F (mL/min/kg) N/A N/A N/A N/A 0.248 0.212 0.230 0.318
C0 (μg/mL) 6.163 5.257 5.930 7.631 N/A N/A N/A N/A
CMAX (μg/mL) N/A N/A N/A N/A 1.314 .826 1.368 1.776
TMAX (hr) N/A N/A N/A N/A 21.4 12.0 24.0 24.0
T ½ λz (hr) 17.4 16.2 16.8 20.7 22.7 18.0 21.9 30.8
λz (1/hr) 0.0398 0.0335 0.0413 0.0428 0.0306 0.0225 0.0316 0.0386
MRT (hr) 20.6 17.7 20.0 26.5 41.7 35.4 40.7 51.3
Vss (L/kg) 0.235 0.206 0.237 0.282 N/A N/A N/A N/A
Vz (L/kg) 0.286 0.213 0.293 0.365 N/A N/A N/A N/A
Vz/F (L/kg) N/A N/A N/A N/A 0.487 0.331 0.464 0.748
Dose (mg/kg) 0.50 0.49 0.50 0.51 1.0 1.0 1.0 1.1
MAT (hr) N/A N/A N/A N/A 20.8 13.9 22.6 24.8
F N/A N/A N/A N/A 0.76 0.48 0.85 0.92
Meloxicam noncompartmental pharmacokinetics (WinNonlin 5.2, Pharsight Inc. Cary NC, USA).
AUC extrapolated = percent of the AUC extrapolated; AUCINF = area under the curve extrapolated to infinity; Cl = plasma clearance; Cl/F = Cl per fraction of the
dose absorbed; C0 = Concentration extrapolated to time 0 using log-linear regression of the first two time points; TMAX = time to CMAX; T ½ λz = terminal half-life;
λz = terminal rate constant; MRT = mean residence time extrapolated to infinity; Vss = volume of distribution at steady state; Vz = volume of distribution, area
method; Vz/F = Vz per fraction of the dose absorbed; MAT = mean absorption time; F = fraction of the dose absorbed.
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is the more correct weight of the animal. This animal did
consistently exhibit the lowest concentration for all time
points when compared to IV administrations in all other
animals, which suggests that the IV dosage administered
may have been less than the targeted 0.5 mg/kg (calcu-
lated as 0.43 mg/kg based on the second weight). How-
ever, the variation in the data was minimal, and there
was found to be no statistically significant difference
between the calculated mean pharmacokinetic para-
meters whether data from this animal was included or
not included in the final calculations. Additionally, as the
incorrect weight was determined to be that used for IV
administration, this minor discrepancy should not affect
the overall evaluation of the data, especially in regards to
oral bioavailability and pharmacokinetics.
As venous access in llamas is challenging and is gener-
ally reserved for direct use by veterinarians, oral admin-
istration is the preferred route over intravenous
administration in field settings. Table 3 demonstrates the
differences in the pharmacokinetic parameters in llamas
of the NSAIDS that have been reported in the literature
to date: meloxicam (present study), flunixin meglumine
[6], ketoprofen [7], and phenylbutazone [8]. Of the four,
PK values for oral administration have only been
reported for phenylbutazone previously, and now melox-
icam, while IV data is available for all four compounds
studied. In comparison to oral administration of phenyl-
butazone, oral meloxicam exhibits similar AUCINF and
oral bioavailability but reaches TMAX much later
(21.4 hrs vs 4.4 hrs) and also possesses a much longer
half-life (17.9 hrs vs. 7.1 hrs) even though plasma drug
concentrations are detected within 30 minutes of admin-
istration. Therefore, oral administration of phenylbuta-
zone could potentially provide therapeutic effects more
rapidly than meloxicam, however, may not reach plasma
levels considered to be therapeutic when compared to
those reported in equine pharmacodynamic studies
(EC50 ranging from 3.6 μg/mL to 15 μg/mL) [8,15,16].
The pharmacokinetic parameters of phenylbutazone also
suggest a much shorter duration of effect when com-
pared to meloxicam while requiring more frequent dos-
ing with extended duration dosing regimens. In addition
to the potential for oral administration, the ideal NSAID
should not require multiple doses per day and should
minimize the overall number of administration periods
necessary to achieve adequate levels of drug concentra-
tion. In this regard, oral meloxicam offers a more desir-
able pharmacokinetic profile over oral phenylbutazone
for longer term NSAID therapy in llamas.
When administered IV, T ½ λz of meloxicam is sub-
stantially greater than in other NSAIDS studied thus far
(17.6 hrs vs. 1.5–5.5 hrs); this is directly related to a
slower clearance rate of meloxicam when compared to
the previously studied NSAIDS (0.19 vs. 0.43–1 .11 mL/
min/kg). Volume of distribution was also greater with
meloxicam than with the other NSAIDS (0.235 vs. 0.03–
0.195 L/kg), although all values can be considered to be
within the range of a low volume of distribution. Most
NSAIDS exhibit a high degree of protein binding which
causes relatively low volume of distribution into the
interstitial fluids but facilitates passage into areas of
Table 2 Results of complete blood count and serum
chemistries pre- and post- meloxicam treatment
Pre-tx Post-tx
Parameter Reference Mean Mean
(Units) Ranges† (min – max) (min – max)
Sodium
(mEq/L)
146 – 156 153.83
(149–156)
151.17
(149–153)
Chloride
(mEq/L)
109 – 125 115
(111–118)
118.83*
(118–120)
Potassium
(mEq/L)
3.8 – 7.3 4.13
(3.8-4.4)
4.35
(4.0-4.5)
Calcium
(mg/dL)
8.4 – 10.8 9.2
(8.7-9.7)
9.3
(8.7-10.0)
Bicarbonate
(mEq/L)
19 – 29 29.67
(27–33) a
22.67*
(22–24) a
BUN
(mg/dL)
24 – 44 15.00
(10–20) b
21.17*
(17–25) b
Creatinine
(mg/dL)
1.5 – 2.7 1.8
(1.7-2.0)
1.43**
(1.3-1.5) a
Total Protein
(gm/dL)
5.3 – 7.3 5.83
(5.3-6.2)
5.87
(5.4-6.1)
Albumin
(gm/dL)
3.0 – 4.2 2.67
(2.2-2.9) b
2.85
(2.4-3.3) b
GGT
(IU/L)
27 – 78 41.83
(31–55)
49.83
(33–89) a
AST
(IU/L)
66 – 235 342.67
(156–1150) a
319
(146–926) a
ALP
(IU/L)
12 – 97 49.17
(36–75)
55.83
(39–82)
Total bilirubin
(mg/dL)
0.0 – 0.3 <.1 <.1
Triglycerides
(mg/dL)
6 – 43 21.67
(17–25)
18.83
(10–26)
NEFA
(mmol/L)
0 – 0.6 { 0.09
(0.01-0.21)
0.04*
(0.01-0.08)
WBC
(x10^3/μL)
8.0 – 21.4 9.89
(4.06-17.45) a
9.84
(5.39-14.44) a
RBC
(x10^6/μL)
10.1 – 17.3 9.47
(8.16-10.9) a
9.40
(7.97-10.69) a
PCV
(%)
27 – 45 25.25
(21.5-28) a
24.67
(21.5-28) a
Fibrinogen
(mg/dL)
100 – 500 283
(200–400)
316
(200–500)
* = p value <0.05 for change in values between pre- and post-treatment samples.
** = p value <0.01 for change in values between pre- and post-treatment
samples.
a = results contain values outside of reference ranges.
b = results for all animals were outside of reference ranges.
† = adult llama reference ranges obtained from the Clinical Pathology
Laboratory, College of Veterinary Medicine, Oregon State University [14].
{ = normal range not provided from lab, utilized range from Tornquist et al 1999.
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inflammation with leakage of plasma proteins into exud-
ate [17]. These data suggest that if IV administration is
chosen over oral, IV meloxicam will still provide a
longer duration of activity than all other NSAIDS stud-
ied thus far in llamas. Interestingly, the finding of a
longer T ½ λz following oral versus IV meloxicam
administration in llamas is similar to the results seen in
other ruminant or pseudo-ruminant species studied thus
far (cattle, sheep, and goats) [18]. The elimination half-
life is determined by the clearance and the volume of
distribution of a drug and is typically the same irrespect-
ive of the route of administration. However, in cases
where the rate of elimination is faster than the rate of
absorption, the terminal slope is not parallel after oral
administration because this reflects the absorption half-
life rather than the elimination half-life. This is an
example of “flip-flop” kinetics and has also been
described after oral administration of meloxicam in other
ruminants most likely because the rumen delays absorp-
tion of the drug from the gastrointestinal tract [18].
The pharmacokinetic parameters of most NSAIDS
have been demonstrated to be species dependent, and
meloxicam has proven to be no exception. Tables 4
and 5 list the differences in pharmacokinetic parameters
of meloxicam in various domesticated large animal species
[18-22]. The most closely related species studied thus far
has been camels, however, only IV administration was
evaluated in that study. The half-life of oral meloxicam in
llamas (22.7 hrs) appears to be similar to species such as
cattle (27.5 hrs) [18] and cats (24 hrs) [23] but is much
slower than in other species such as goats (11.8 hrs) [19]
and dogs (12.1 hrs) [24]. In contrast, TMAX exhibits extre-
me variation, with llamas taking the longest time to reach
maximum concentration (21.4 hrs) and horses the short-
est (1.5 hrs) [20]. In addition to formulation, one import-
ant factor that has been suggested to affect the availability
Table 4 Comparison of pharmacokinetic parameters of meloxicam in domestic animal species, PO administration
PO administration (mean values)
Parameter Llamas* Cattle* Goats* Horses ** Sheep*
(Units) (present study) [18] [19] [20] [21]
AUCINF (hr*μg/mL) 68.35 164.46 23.24 NR 75.09
Cl/F (mL/min/kg) 0.248 0.1 NR NR 0.220
CMAX (μg/mL) 1.31 3.10 0.736 1.73 1.715
TMAX (hr) 21.4 11.64 15 3.4 19.0
T ½ λz (hr) 22.7 27.54 11.8 NR 15.4
Vz/F (L/kg) 0.487 0.242 NR NR 0.293
Dose (mg/kg) 1.0 1.0 0.5 0.6 0.99
F (%) 76.0 100.0 79.0 95.6 72.0
NR = not reported.
* Non-compartmental pharmacokinetic analysis.
** Compartmental pharmacokinetic analysis.
AUCINF = area under the curve extrapolated to infinity; Cl/F = Cl per fraction of the dose absorbed; CMAX = maximum plasma concentration; TMAX; = time to CMAX;
T ½ λz, T ½β = terminal half-life; Vz/F = Vz per fraction of the dose absorbed; F = fraction of the dose absorbed.
Table 3 Comparison of pharmacokinetic parameters of common NSAIDS in llamas
IV dosages (mean values) PO dosages (mean values)
Parameter
(Units)
Meloxicam
(present study)
Phenylbutazone
[8]
Ketoprofen [7]* Flunixin meglumine
[6]
Meloxicam
(present study)
Phenylbutazone
[8]S R Sum
AUC (hr*μg/mL) 43.96 80.1 168.9 176.4 345.3 49.0 68.35 60.8
Cl (mL/min/kg) 0.190 1.11 0.22 0.21 0.43 0.78 N/A N/A
TMAX (hr) N/A N/A N/A N/A 21.4 4.37
T ½ λz (hr) 17.4 2.03 5.49 5.41 5.45 1.47 22.7 7.09
Vss (L/kg) 0.235 0.155 0.100 0.095 0.195 0.030 N/A N/A
Dose (mg/kg) 0.50 5.0 2.2 2.2 4.4 2.2 1.0 5
F (%) N/A N/A N/A N/A 76.0 69.9
* For the ketoprofen study, a racemic mixture of S and R enantomers were administered to each animal. PK values from each enantomer as well as the sum (or in
the case of half –life, average) of both are reported here.
AUC = area under the curve extrapolated to infinity; Cl = plasma clearance; TMAX; = time to CMAX; T ½ λz = terminal half-life; Vss = volume of distribution at steady
state; F = fraction of the dose absorbed.
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of NSAIDS for absorption, alter TMAX and increase half-
life in herbivores is binding of the drugs to hay and
digesta; however this affect was shown to vary consider-
ably with the specific drug studied [25]. A recent study
comparing the pharmacokinetics in ruminant calves fed
grass hay versus pre-ruminant calves fed milk replacer
and calf starter showed no statistically significant differ-
ence in the Tmax or T ½ λz between ruminant and non-
ruminant diets [26]. In addition to anatomic differences
and types of feed provided, differing pH of the stomach
compartments in ruminant (or ruminant-like) and non-
ruminant animals may serve to affect the site, and thus
the timing, of meloxicam absorption, as absorption is
favored in relatively acidic areas of the gastrointestinal
tract [26]. In addition, certain species-specific factors,
such as increased drug metabolism, may also play a key
role in determining pharmacokinetic differences.
In the present study, the half-life of IV meloxicam was
17.4 hrs, which falls in the middle of the range of half-
lives observed in other domestic large animal species
(from 8.5 hrs in horses to 40.2 hrs in camels) [20,22].
The volume of distribution after IV administration was
0.235 L/kg, which is towards the higher end of the range
within the species reported (from 0.093 L/kg in camels
to 0.245 L/kg in goats) [19,22] but is still considered to
be a relatively low volume of distribution consistently
observed with most NSAIDS. The AUCINF in llamas of
46.96 hr*μg/mL was higher than that reported in goats
(29.74 hr*μg/mL) [19] but lower than that reported in
cattle (82.34 hr*μg/mL) [18] given the same dosage of
0.5 mg/kg. In contrast, however, the AUCINF for camels
was markedly higher at 346.7 hr*μg/mL with only a
slightly higher dosage of 0.6 mg/kg IV [22]. The extreme
variation in AUCINF can be attributed to differences in
clearance rates between species which range from
0.032 mL/min/kg in camels [22] to 0.298 mL/min/kg in
goats [19], and underscores the need for pharmacokinetic
studies in the species of interest to determine accurate
estimates of drug concentrations after administration.
The actual therapeutic concentration range in llamas
for meloxicam, as well as all other NSAIDS, is unknown.
Target ranges for pain relief due to experimentally
induced arthritis in horses based on the estimated EC50
value (concentrations that provide 50% of the maximum
effect) have been suggested to be >0.2 μg/mL [27] which
may allow for cautious extrapolation that this concentra-
tion may provide similar therapeutic pain relief benefits
in llamas. At an oral dose of 1 mg/kg, concentrations
of >0.2 μg/mL are maintained for at least 72 hours,
suggesting that a single dosage of oral meloxicam at
1 mg/kg could potentially maintain therapeutic concen-
trations for pain relief in plasma for 2–3 days in adult
llamas. Utilizing the plasma clearance and the oral bio-
availability established in this study and a dose of 1 mg/
kg, an average concentration at steady state can be esti-
mated to be 2,734 ng/mL with daily dosing, and
1,367 ng/mL when administered every other day. The
calculation of the average therapeutic concentrations in
plasma during a dose interval in other species from
approved maintenance dose and reported clearance
values varies from 347 ng/mL in cats, 735 ng/mL in
horses to 833 ng/mL in dogs and 1389 ng/mL in humans
[19]. This variation makes extrapolations of therapeutic
concentrations between species difficult. Additionally,
the potential exists for increased risk of adverse effects
due to dose accumulation, especially at once daily dos-
ing. To determine optimal dosing and treatment inter-
vals necessary to ensure adequate tissue concentrations
for clinical efficacy, further studies combining pharma-
codynamics with pharmacokinetics and safety trials in
llamas are recommended. In addition, various stressors
such as disease, inflammation, pregnancy, and lactation
have all been shown to affect the pharmacokinetics of
medications [28], thus the data reported here may not
Table 5 Comparison of pharmacokinetic parameters of meloxicam in domestic animal species, IV administration
IV administration (mean values)
Parameter Llamas* Cattle* Goats* Horses** Sheep* Camels*
(Units) (present study) [18] [19] [20] [21] [22]
AUCINF (hr*μg/mL) 43.96 82.34 29.74 NR 49.26 346.7
Cl or ClT (mL/min/kg) 0.190 0.1 0.298 0.34 0.169 0.032
C0 (μg/mL) 6.16 5.93 3.12 NR 4.96 NR
T ½ λz or T ½β (hr) 17.4 20.35 10.9 8.54 14.0 40.2
Vss (L/kg) 0.235 0.171 0.245 0.12 178.7 0.093
Dose (mg/kg) 0.5 0.5 0.5 0.6 0.5 0.6
NR = not reported.
* Non-compartmental pharmacokinetic analysis.
** Compartmental pharmacokinetic analysis.
AUCINF = area under the curve extrapolated to infinity; Cl = plasma clearance; ClT = total body clearance; C0 = Concentration extrapolated to time 0 using log-
linear regression of the first two time points; T ½ λz, T ½ β = terminal half-life; Vss = volume of distribution at steady state.
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reflect exact PK parameters in diseased states. Alterna-
tive dosing strategies may also be necessary to achieve
appropriate levels of therapy for all targeted outcomes
(pain relief, fever reduction, decrease in inflammation,
or protection against the effects of endotoxin). Until
completion of further studies, it is recommended that
dosing be tailored to the clinical response of the individ-
ual patient to treatment.
No adverse effects were noted in any animals receiving
either oral or IV treatments of meloxicam. To further
evaluate the safety of meloxicam administration in
healthy llamas, complete blood count and chemistry
panels were submitted on all animals prior to and fol-
lowing the second phase of treatment. We were particu-
larly concerned with the effect of treatment on liver and
kidney chemistry values, as renal and hepatic toxicity are
known complications of NSAID use [17]. As reported in
Table 2, all animals consistently displayed a mild hypoal-
buminemia and decreased BUN prior to treatment,
while five of the six displayed a mild anemia in compari-
son to the references ranges. These abnormalities may
be related to the use of standard reference ranges from
Oregon State University Diagnostic Laboratory instead
of validation of in-house reference ranges, as differences
in instrumentation can lead to variability in results.
Decreased BUN and albumin can also be related to feed-
ing of a low protein diet [29]. The level of BUN did in-
crease in a statistically significant manner after treatment
with meloxicam, however, the average value was still con-
sidered to be lower than the reference range. As these
animals were housed at their home farm in between
treatment phases, the potential exists for differences in
fed protein levels between home farm (pre-treatment)
and university (post-treatment) feed sources. Mild
anemia and hypoalbuminemia can also be related to in-
testinal parasitism, which is common in camelids. Fecal
samples were taken from 4 of the 6 animals with the low-
est hematocrit for McMaster’s Quantitative Fecal Egg
Counts; 2 of the 4 were negative for parasite detec-
tion, while the other 2 exhibited only very low levels
(<100 eggs/gram of Trichostrongyles) of intestinal para-
sites. This alone is cannot completely rule out current
intestinal parasitism as the cause of the mild anemia and
hypoproteinemia; in addition, the history of anti-
parasiticide administration is unknown in these animals.
Therefore, recent on-farm deworming may have affected
the results of the fecal exams. The low serum albumin
exhibited by the animals in this study also has the potential
to affect the pharmacokinetic data of meloxicam as
NSAIDS are typically highly bound to plasma proteins [17];
however, there is no evidence available to demonstrate that
it impacted the results presented in this study.
One animal exhibited a significantly elevated AST
level pre-treatment that had decreased slightly by the
post-treatment sample but was still elevated; this animal
was otherwise apparently healthy for the entire duration
of the study. All other animals had normal AST values
pre-treatment; in 2 of the 5 remaining animals, AST
levels were increased above pre-treatment levels in post-
treatment samples, however, only 1 additional animal
exhibited AST levels greater than the reference range
post-treatment. The difference in AST between pre- and
post-treatment blood samples was not considered to be
statistically significant. One animal exhibited elevated
GGT following treatment, but overall change in GGT for
all animals was not statistically significant. Statistically
significant increases were seen in chloride, while statisti-
cally significant decreases were noted with bicarbonate,
non-esterified fatty acids (NEFAs) and creatinine. How-
ever, all values for these parameters were still within
normal references ranges and thus the differences are
not considered to be biologically significant. Further
studies involving multiple dosages and increased dur-
ation of therapy would be warranted to verify that there
are no negative effects on either kidney or liver function
with prolonged therapy.
In addition to risk of nephrotoxicity and hepatotoxicity,
NSAID usage has been commonly recognized as a risk
factor for gastric ulceration in many species, including
humans, cats, dogs and horses, and it has been suggested
as a potential risk factor for ulceration of the third com-
partment of the camelid stomach (C3) [30,31]. In llamas,
C3 ulcers are a commonly encountered gastrointestinal
disorder, however, there is a lack of scientific data detailing
the pathogenesis of ulcer formation in this species [31,32].
It has been suggested that stress, especially related to
disease and chronic disorders or isolation from herd
mates, may play a role in the development of ulcerations
in llamas [31]. Non-selective NSAIDS decrease the pro-
duction of prostaglandins thought to be important in
maintaining mucosal blood flow and mucous secretion in
mammals; it is a combination of this and other effects that
is thought to lead to gastric ulceration with NSAID use
[33]. Previous studies involving daily intramuscular ad-
ministration of 1.1 mg/kg flunixin meglumine have
demonstrated a lack of statistically significant gastric pH
reduction and ulcer formation in llamas, which led the
authors of that study to suggest that NSAIDS may not
exert similar ulcerogenic effects in this species [34]. How-
ever, recent literature reviews on NSAID-induced gastro-
pathy do not suggest direct reduction of pH as an
inciting cause of ulceration [17,33,35]. Thus, with a lack
of strong scientific data to suggest that NSAIDS do not
exert an ulcerogenic effect in llamas, it may be prudent
to utilize NSAIDS such as meloxicam that have exhib-
ited improved GI safety profiles in other species [36].
Although reports vary, extensive work in humans sug-
gests that while not completely free from GI-related side
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effects, there is a greater GI safety profile for COX-2
selective inhibitors in comparison to non-selective inhi-
bitors [17,36-38]. Meloxicam is generally considered to
be a COX-2 selective drug; however, studies have shown
that there can be much variability between species in the
preference of inhibition of cyclooxygenase-1 versus
cyclooxygenase-2 for a given drug. In humans, meloxi-
cam demonstrates a significant and long lasting prefer-
ence for inhibition of COX-2 while having much less
activity against COX-1 [39]. In dogs, in vitro assays sug-
gest that meloxicam ranges from 3.7 to 12 times more
effective at inhibiting COX-2 versus COX-1 [40-42].
However, in cats, both in vitro and ex vivo studies have
shown a ratio of only 2.7 in regards to selectivity of
COX-2 inhibition over COX-1 [43]. Early meloxicam re-
search in horses also suggests that even though present,
suppression of COX-1 is reversible, and COX-2 inhib-
ition is prolonged at sites of inflammation [44]. There-
fore, meloxicam may offer some selective benefit in
llamas of COX-2 inhibition over the non-selective
NSAIDS, but further studies are warranted to determine
to what extent it can be considered COX-2 selective in
this species.
Conclusions
The results of the present study suggest that oral admin-
istration of meloxicam may offer a practical and long-
acting option for NSAID administration for the relief of
pain and inflammation in llamas. The pharmacokinetic
profile described in this study supports further research
including pharmacodynamic studies and efficacy trials to
best determine appropriate dosage and treatment inter-
vals for certain disorders. Additional studies evaluating
response to multi-day therapy regimens are also war-
ranted to fully assess the pharmacokinetic and safety
profile of this COX-2 selective NSAID in llamas.
Methods
This study was approved by the Institutional Animal
Care and Use Committee at Iowa State University (ISU)
(Protocol # 10-11-7239-V).
Animals and housing
Six healthy adult llamas ranging in age from 2 to 14 years
were used for this study. Mean (± standard deviation)
weights at first and second treatment administra-
tions were 144.0 ± 18.31 kg and 149.8 ± 18.88 kg res-
pectively. Weights for dose calculation were determined
by weighing the llamas 24 hours prior to each treat-
ment administration.
Study animals were placed in group housing at the uni-
versity for 1 day prior to each phase of the study and
returned to their home farm in between study phases.
Housing consisted of an indoor stall with rubber mat
flooring at the Iowa State University Lloyd Veterinary
Medicine Center. All llamas were fed grass hay and water
ad libitum throughout the experiment. Temperature,
pulse, respiration, urination, defecation, attitude and
appetite were monitored throughout each study period.
Experimental design
A cross over study design was used with randomized
assignment of llamas to one of 2 dosing regimens. The
observed washout period between treatment administra-
tions was 11 days.
Approximately 18 hours prior to study commence-
ment, llamas were restrained for intravenous catheter
placement. Llamas that received IV meloxicam were fit
with two catheters. One catheter was designated for
drug administration only and the other solely for blood
sample collection. The area over the cranial portion of
the jugular vein was clipped and disinfected using alter-
nating 70% isopropyl alcohol and chlorhexidine soaked
4x4 gauze. For ease of catheter placement, all animals
were sedated with approximately 0.1 mg/kg of xylazine
IV (AnasedW injection, 100 mg/mL, Lloyd Laboratories,
Shenandoah, IA). The catheter site was infiltrated with
2% lidocaine injection, 1 ml SQ (Hospira Inc, Lake For-
est, IL) prior to placement of catheter and a small stab
incision was made through the skin at the preferred site
for catheter placement. A 14 G x 140 mm catheter
(Abbocath-TW, Hospira, Slingo, Ireland) was placed on
the side designated for blood sample collection (right
jugular), while a 16 G x 51 mm catheter (Abbocath-TW,
Hospira, Slingo, Ireland) was placed on the side desig-
nated for drug administration (left jugular). If unable to
place the 14 G x 140 mm catheter due to the presence
of a valve in the jugular vein, the 16 G x 51 mm catheter
was alternatively placed for the blood draw catheter. All
catheters were sutured to the skin using 2–0 nylon
suture (EthilonW, Ethicon Inc, San Lorento, Puerto Rico)
and a 15.2 cm high flow extension set with reflux valve
(MILA International, Florence, KY) was added to the
catheter to prevent backflow of air and aid in ease of
blood sample collection. Catheter patency was main-
tained using heparin saline flush containing 2 USP units
heparin sodium/mL saline (Heparin Sodium Injection,
B Braun Medical, Irvin, CA).
Each llama was subjected to the following two treat-
ments (n = 3 llama/treatment/period);
1) Intravenous (IV) injection of 0.5 mg/kg of meloxicam
(MetacamW 5 mg/mL solution for injection (NADA
141–219), Boehringer Ingelheim Vetmedica, Inc. St
Joseph, MO; Lot # 2066180) administered as a bolus
in the jugular vein using a designated catheter. The
catheter was flushed with 6 mL of heparin-saline and
removed immediately after flushing.
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2) Oral (PO) meloxicam was administered at 1 mg/kg
(Meloxicam tablets 15 mg (NDC 0378-1089-01),
Mylan Pharmaceuticals, Morgantown, WV; Lot #
3025543). Tablets were dissolved in 50 mL of water
within 60 minutes of administration by stomach
tube. The stomach tube was flushed with 500 mL
of water prior to removal.
The drug doses were selected based on the study
designed used in previous publications that explored the
oral bioavailability of meloxicam in ruminants where it
was expected that drug absorption from the gastrointes-
tinal tract may be diminished [18,21]. The IV dose was
rounded to the nearest 1.0 mL and administered using a
20 mL syringe. The oral dose was rounded to the nearest
whole tablet and administered in water with a 60 mL
catheter tip syringe.
Llamas were manually restrained with a halter and
lead rope for blood collection. In the llamas receiving IV
meloxicam, approximately 6 mL of blood was collected at
0, 3, 6, 10, 20, 40 minutes and 1, 3, 6, 12, 24, 48, 72 and 96
hours after dosing. Llamas receiving oral meloxicam were
blood sampled at 0 and 30 minutes and 1, 2, 4, 6, 8, 10, 12,
24, 48, 72 and 96 hours after administration. Blood was
drawn into a collection syringe and immediately transferred
to lithium heparin vacutainer tubes (HemoGARDW, BD
Diagnostics, Franklin Lakes, NJ). Samples were stored on
ice prior to centrifugation at 5°C for 10 minutes at 1,500 x
g within 120 minutes of collection. Plasma was then
pipetted to cryovials and frozen at −70°C until analysis.
Blood samples from prior to initiation of the second
phase of the trial (t = 0 min) and at 72 hrs post treatment
were also collected into serum (BD VacutainerW, BD
Diagnostics, Franklin Lakes, NJ) and EDTA (Monoject™
15% EDTA(K3), Tyco Healthcare Group, Mansfield MA)
tubes and submitted within 1 hr to the Iowa State Lloyd
Veterinary Medical Center Clinical Pathology Depart-
ment for a complete blood count (CBC) and blood
chemistry to assess the effect of meloxicam treatment
on hematologic parameters in llamas.
A 2-way ANOVA was used to compare hematological
values before treatment [baseline] vs. after treatment as
well as treatment type [oral vs intravenous] in the sec-
ond phase of the study. When the overall treatment
effect was significant, a posthoc Tukey test was used
to determine whether there was a greater change for that
variable before and after exposure to each treatment.
Statistical significance was set a priori at values of
P ≤ 0.05. All statistical analyses were performed by use of
statistical software (JMP 9.0, SAS Institute, Cary, NC).
Plasma drug analysis
Plasma concentrations of meloxicam were determined
using high-pressure liquid chromatography (Surveyor
MS Pump and Autosampler, Thermo Scientific, San Jose,
CA, USA) with mass spectrometry detection (TSQ
Quantum Discovery MAX, Thermo Scientific, San Jose,
CA, USA). Plasma samples, plasma spikes, and plasma
QC samples, 0.200 mL, were treated with 30% perchloric
acid (20 μL) after addition of 40 ng/mL of the internal
standard piroxicam. The samples were vortexed for
5 seconds and centrifuged for 20 minutes at 2,500 × g
to sediment the precipitate. A portion of supernatant,
80 μL, was transferred to an injection vial fitted with
a glass insert containing 120 μL of 1.9% ammonium
hydroxide in 25% aqueous acetonitrile. The injection
volume was set to 12.5 μL. The mobile phases consisted
of A: 0.1% formic acid in water and B: 0.1% formic
acid in acetonitrile at a flow rate of 0.225 mL/min. The
mobile phase began at 25% B with a linear gradient to
95% B at 7 minutes, which was maintained for 1.5 min-
utes, followed by re-equilibration to 25% B. Separation
was achieved with a solid-core C18 column (KinetexXB
-C18, 100 mm×2.1 mm, 2.6 μm particles, Phenomenex,
Torrance, CA, USA) maintained at 40°C. Piroxicam
eluted at 4.85 minutes and meloxicam at 5.95 minutes.
Four SRM transitions were monitored for meloxicam
and three SRM transitions were used with the internal
standard, piroxicam. The quantifying ions for meloxicam
were 72.99, 88.01, 114.99, and 140.98 m/z and 77.97,
94.98, and 120.98 m/z for piroxicam. Sequences consist-
ing of plasma blanks, calibration spikes, QC samples,
and llama plasma samples were batch processed with a
processing method developed in the Xcalibur software
(Thermo Scientific, San Jose, CA, USA). The processing
method automatically identified and integrated each
peak in each sample and calculated the calibration curve
based on a weighted (1/X) linear fit. Plasma concentra-
tions of meloxicam in unknown samples were calculated
by the Xcalibur software based on the calibration curve.
Results were then viewed in the Quan Browser portion
of the Xcalibur software. The standard curve in llama
plasma was linear from 0.005 to 10.0 μg/mL. The coeffi-
cient of determination (R squared) exceeded 0.995 and
all measured values were within 15% of the actual values
with most of the values less than 5% difference from the
actual values. The accuracy of the assay for meloxicam
in llama plasma was 99 ± 3% of the actual concentration
while the coefficient of variation was 5% determined on
4 sets of replicates for each of the following concentra-
tions: 0.015, 0.15, and 1.5 μg/mL. The limit of quantita-
tion (LOQ) for this assay was determined to be 0.005
ug/mL, while the limit of detection (LOD) was 10-fold
lower than that at 0.0005 ug/mL.
Pharmacokinetic analysis
Pharmacokinetic analyses were performed with com-
puter software (WinNonlin 5.2, Pharsight Corporation,
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Mountain View, CA, USA) using noncompartmental
methods. The variables calculated included the area
under the curve from time 0 to infinity (AUCINF) using
the linear trapezoidal rule, area under the first moment
curve from time 0 to infinity (AUMCINF), plasma clear-
ance (Cl), plasma clearance per fraction of the dose
absorbed (Cl/F), apparent volume of distribution at
steady state (Vss), apparent volume of distribution of the
area (Vz), apparent volume of distribution of the area
per fraction of the dose absorbed (Vz/F), first-order
rate constant (λz), terminal half-life (T½ λz), and mean
residence time extrapolated to infinity (MRT). The max-
imum serum concentration (CMAX) and time to max-
imum serum concentration (TMAX) were determined
directly from the data. The concentration at time 0 (C0)
was calculated by log-linear regression using the first
two time points after IV administration. The mean ab-
sorption time (MAT) was calculated by subtracting the
IV MRT from the PO MRT. The fraction of the dose
absorbed (F) for oral meloxicam was determined by div-
iding the AUCINF per dose after oral administration by
the AUCINF per dose after IV administration.
In order to determine if the outlier data observed
in one animal due to an error in bodyweight determin-
ation prior to study commencement significantly affected
the mean calculated pharmacokinetic parameters, a
Wilcoxon-rank sum test was used to compare non-
normally distributed data (TMAX, MAT) and a Students
t-test was used for normally distributed data including
and excluding the outlier. Statistical significance was
designated a priori as p< 0.05. All statistical analyses
were performed by use of statistical software (JMP 9.0,
SAS Institute, Cary, NC).
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